ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results